247 related articles for article (PubMed ID: 23099118)
1. Relationship of NAT2, CYP2E1 and GSTM1/GSTT1 polymorphisms with mild elevation of liver enzymes in Brazilian individuals under anti-tuberculosis drug therapy.
Forestiero FJ; Cecon L; Hirata MH; de Melo FF; Cardoso RF; Cerda A; Hirata RD
Clin Chim Acta; 2013 Jan; 415():215-9. PubMed ID: 23099118
[TBL] [Abstract][Full Text] [Related]
2. Association of NAT2, GST and CYP2E1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity.
Singla N; Gupta D; Birbian N; Singh J
Tuberculosis (Edinb); 2014 May; 94(3):293-8. PubMed ID: 24637014
[TBL] [Abstract][Full Text] [Related]
3. Relationship between genetic polymorphisms of drug-metabolizing enzymes (CYP1A1, CYP2E1, GSTM1, and NAT2), drinking habits, histological subtypes, and p53 gene point mutations in Japanese patients with gastric cancer.
Suzuki S; Muroishi Y; Nakanishi I; Oda Y
J Gastroenterol; 2004; 39(3):220-30. PubMed ID: 15064998
[TBL] [Abstract][Full Text] [Related]
4. The incidence of liver injury in Uyghur patients treated for TB in Xinjiang Uyghur autonomous region, China, and its association with hepatic enzyme polymorphisms nat2, cyp2e1, gstm1 and gstt1.
Xiang Y; Ma L; Wu W; Liu W; Li Y; Zhu X; Wang Q; Ma J; Cao M; Wang Q; Yao X; Yang L; Wubuli A; Merle C; Milligan P; Mao Y; Gu J; Xin X
PLoS One; 2014; 9(1):e85905. PubMed ID: 24465778
[TBL] [Abstract][Full Text] [Related]
5. CYP1A1, CYP2D6, CYP2E1, NAT2, GSTM1 and GSTT1 polymorphisms or their combinations are associated with the increased risk of the laryngeal squamous cell carcinoma.
Gajecka M; Rydzanicz M; Jaskula-Sztul R; Kujawski M; Szyfter W; Szyfter K
Mutat Res; 2005 Jul; 574(1-2):112-23. PubMed ID: 15914211
[TBL] [Abstract][Full Text] [Related]
6. Genetic interaction between NAT2, GSTM1, GSTT1, CYP2E1, and environmental factors is associated with adverse reactions to anti-tuberculosis drugs.
Costa GN; Magno LA; Santana CV; Konstantinovas C; Saito ST; Machado M; Di Pietro G; Bastos-Rodrigues L; Miranda DM; De Marco LA; Romano-Silva MA; Rios-Santos F
Mol Diagn Ther; 2012 Aug; 16(4):241-50. PubMed ID: 22788240
[TBL] [Abstract][Full Text] [Related]
7. Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: a meta-analysis.
Sun F; Chen Y; Xiang Y; Zhan S
Int J Tuberc Lung Dis; 2008 Sep; 12(9):994-1002. PubMed ID: 18713495
[TBL] [Abstract][Full Text] [Related]
8. Genetic polymorphisms in metabolic enzymes and susceptibility to anti-tuberculosis drug-induced hepatic injury.
Feng FM; Guo M; Chen Y; Li SM; Zhang P; Sun SF; Zhang GS
Genet Mol Res; 2014 Nov; 13(4):9463-71. PubMed ID: 25501156
[TBL] [Abstract][Full Text] [Related]
9. Association of genetic polymorphisms of
Yang S; Hwang SJ; Park JY; Chung EK; Lee JI
BMJ Open; 2019 Aug; 9(8):e027940. PubMed ID: 31375612
[TBL] [Abstract][Full Text] [Related]
10. Polymorphisms of NAT2, CYP2E1, GST, and HLA related to drug-induced liver injury in indonesian tuberculosis patients.
Perwitasari DA; Darmawan E; Mulyani UA; Vlies PV; Alffenaar JC; Atthobar J; Wilffert B
Int J Mycobacteriol; 2018; 7(4):380-386. PubMed ID: 30531039
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients.
Teixeira RL; Morato RG; Cabello PH; Muniz LM; Moreira Ada S; Kritski AL; Mello FC; Suffys PN; Miranda AB; Santos AR
Mem Inst Oswaldo Cruz; 2011 Sep; 106(6):716-24. PubMed ID: 22012226
[TBL] [Abstract][Full Text] [Related]
12. Association of isoniazid-metabolizing enzyme genotypes and isoniazid-induced hepatotoxicity in tuberculosis patients.
Sotsuka T; Sasaki Y; Hirai S; Yamagishi F; Ueno K
In Vivo; 2011; 25(5):803-12. PubMed ID: 21753138
[TBL] [Abstract][Full Text] [Related]
13. CYP2E1, GSTM1 and GSTT1 genetic polymorphisms and susceptibility to antituberculosis drug-induced hepatotoxicity: a nested case-control study.
Tang SW; Lv XZ; Zhang Y; Wu SS; Yang ZR; Xia YY; Tu DH; Deng PY; Ma Y; Chen DF; Zhan SY
J Clin Pharm Ther; 2012 Oct; 37(5):588-93. PubMed ID: 22335459
[TBL] [Abstract][Full Text] [Related]
14. N-acetyltransferase 2, cytochrome P4502E1 and glutathione S-transferase genotypes in antitubercular treatment-induced hepatotoxicity in North Indians.
Rana SV; Sharma SK; Ola RP; Kamboj JK; Malik A; Morya RK; Sinha SK
J Clin Pharm Ther; 2014 Feb; 39(1):91-6. PubMed ID: 24188272
[TBL] [Abstract][Full Text] [Related]
15. Genetic polymorphisms of CYP2E1, GST, and NAT2 enzymes are not associated with risk of breast cancer in a sample of Lebanese women.
Zgheib NK; Shamseddine AA; Geryess E; Tfayli A; Bazarbachi A; Salem Z; Shamseddine A; Taher A; El-Saghir NS
Mutat Res; 2013; 747-748():40-7. PubMed ID: 23628324
[TBL] [Abstract][Full Text] [Related]
16.
Jaramillo-Valverde L; Levano KS; Tarazona DD; Vasquez-Dominguez A; Toledo-Nauto A; Capristano S; Sanchez C; Tarazona-Santos E; Ugarte-Gil C; Guio H
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232322
[TBL] [Abstract][Full Text] [Related]
17. Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis.
Cho HJ; Koh WJ; Ryu YJ; Ki CS; Nam MH; Kim JW; Lee SY
Tuberculosis (Edinb); 2007 Nov; 87(6):551-6. PubMed ID: 17950035
[TBL] [Abstract][Full Text] [Related]
18. Influence of CYP1A1, CYP2E1, GSTM3 and NAT2 genetic polymorphisms in oral cancer susceptibility: results from a case-control study in Rio de Janeiro.
Marques CF; Koifman S; Koifman RJ; Boffetta P; Brennan P; Hatagima A
Oral Oncol; 2006 Jul; 42(6):632-7. PubMed ID: 16488179
[TBL] [Abstract][Full Text] [Related]
19. Influence of CYP2C9, GSTM1, GSTT1 and NAT2 genetic polymorphisms on DNA damage in workers occupationally exposed to organophosphate pesticides.
Singh S; Kumar V; Singh P; Banerjee BD; Rautela RS; Grover SS; Rawat DS; Pasha ST; Jain SK; Rai A
Mutat Res; 2012 Jan; 741(1-2):101-8. PubMed ID: 22108250
[TBL] [Abstract][Full Text] [Related]
20. CYP1A2*1C, CYP2E1*5B, and GSTM1 polymorphisms are predictors of risk and poor outcome in head and neck squamous cell carcinoma patients.
Olivieri EH; da Silva SD; Mendonça FF; Urata YN; Vidal DO; Faria Mde A; Nishimoto IN; Rainho CA; Kowalski LP; Rogatto SR
Oral Oncol; 2009 Sep; 45(9):e73-9. PubMed ID: 19442564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
